Advertisement
Advertisement
U.S. Markets open in 7 hrs 50 mins
Advertisement
Advertisement
Advertisement
Advertisement

Atreca, Inc. (BCEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.8300+0.0650 (+3.68%)
At close: 04:00PM EDT
1.8400 +0.01 (+0.55%)
After hours: 06:35PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • C
    Common Sense
    I'm expecting this to jump to $8.71 by the end of the month...
  • C
    Common Sense
    How low can we go?
  • C
    Common Sense
    Amateurs think about how much money they can make. Professionals think about how much money they could lose. Since I started coping trading signals from Mrs Elizabeth Towles I have made over $523k in the three months I used her signals. She is so professional. this is so amazing😌.You can reach out to her on Whats 🌍app 👉👉👉+1 424 588-2076
  • M
    Mike
    That sure was a fun way to lose 20 grand in a day.
  • D
    Divad
    Uh oh, things are brewing after hours. Just the start of a nice run next week for sure. Oversold + low float + more cash than the market cap + 400% upside potential. I'll take this all day long.
    Bullish
  • A
    Anonymous
    this will quadruple from here so not selling for less than $12
    Bullish
  • C
    Chan
    BCEL will get back to its fair value which, should be 12.50-15.50 bucks/share range soon . MHO!
  • P
    Paul
    Don't get me wrong, I bought more today, but people should understand that the study results were pretty underwhelming. Expression of the ATRC-101 target was highly variable, even though the patient cohort was pre-screened. In 12 of 20 study participants, the cancer kept progressing after ATRC-101 treatment. Only 3 patients showed a reduction in tumor size.

    It wasn't all bad: Treatment effectiveness did seem to be related to expression of the ATRC-101 target, and they may be able to develop better screening for patients that will respond best to ATRC-101. But it's a far cry from the sort of spectacular results they were seeing in the mouse model.

    It wasn't a home run, and that's what a lot of biotech speculators are trolling for, the next home run. So they're headed to the exits. This will take patience.
  • k
    k
    Sells with Stop-loss-limits. Those are visible for marketmakers. You could see that someone was dropping the price to get them. No bad news hidden in the report, but they try to make the impression that it was. Many people will not read the report, just assume it must be bad, if the price is down 30% on news.
  • C
    Common Sense
    20% gain so far today. I wonder why?
  • #
    #Mike@
    Happy New Year, folks!!
    The recent insider buyings confirm that Q1 2022 will unleash our potential: $ 25+++ very very 🔜🙏
    Bullish
  • J
    James
    To date, twenty patients have been enrolled and treated in trial evaluating ATRC-101 in multiple solid tumours. Enrolment has been completed in the fourth cohort (10 mg/kg) of the dose escalation portion. No DLTs have been observed. The company and investigators decided, out of an abundance of caution, to enrol three additional patients in the fourth dose cohort, after the first two patients enrolled experienced rapid deterioration associated with disease progression, assessed as unrelated to ATRC-101, relatively soon after completion of the DLT assessment period. They anticipate commencing enrolment in the fifth and final cohort shortly, pending review, and expect to announce initial summary data from the trial in July.

    Enrolment includes additional patients treated through backfill of the third dose escalation cohort and the initiation of a mono dose expansion cohort, as previously disclosed. They expect to enrol additional cohorts evaluating 101 in combination with an anti-PD-1 and in combo with a chemo agent in 2Q and 2H, respectively.
  • V
    VM7
    Market Cap = $217 m.
    Cash (6/30) = $182 m
    Enterprise Value = Value Attached to the Pipeline = $ 35 m
    R&D expensed in the last 3.5 years = $ 187 m

    It is trading at essentially 20 cents/$1.00 of R&D in the last 3.5 years. It does not make any sense.

    My 2 cents.
  • J
    James
    The company will host a webinar to present initial data from the dose escalation portion of its ongoing PhI trial evaluating ATRC-101 in select solid tumour types on Thursday, 29, at 8:00 a.m. ET
  • R
    Rock
    Regret I didn’t buy last week
  • w
    wscott
    Man…women and child, I hope the drug works…. (For all the right reasons)
    Their lead drug ATRC101 binds to a RNP complex acting as a flagpost initiating an innate and adaptive immune response. Its a very abundant protein but tumors seem to produce their own version of this RNP complex. ATRC reacted 50% of the time in ~1000’s of different tumor type samples. That means a 50 % chance of a response as monotherapy(more on combo later).
    This specific tumor RNP happens in autoimmune disease but was unbeknownst to science in cancer prior to Atreca’s discovery and unlikely to be discovered without Atreca’s platform and approach. Hence when validated this is a huge breakthrough “foundational drug” like PD1 and CD47.
    PD1 drugs like keytruda form 1/3 of Merck’s entire revenue at 14B even though it works for only 25% of patients. Its the highest revenue generating cancer and drug top 5 drugs by revenue on the planet. ATRC101 is looking to enhance PD1 response, work synergistically or in many cases replace PD1 entirely
  • C
    Common Sense
    Nice gain today. Hopefully, just the beginning of a long run.
  • C
    Common Sense
    Glad I bought another 600 yesterday at $1.68
  • w
    wscott
    Overdone as the results were quite in line with reasonable expectations re safety and hints of efficacy that support mechanism of action in humans consistent with preclinical animal model. .. but even more selling to come so keep some powder dry if you like me are picking some shares up in this fire sale
Advertisement
Advertisement